Drugs / NOC-110
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06504446 | Sep 2024 → Jun 2026 overdue | — | Nocion Therapeutics | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NOC-110 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06504446 ↗ |
| Route | Inhaled | “NOC-110 (taplucainium) administered by daily dry powder inhalation.” NCT06504446 ↗ |